Peter Rossing
Overview
Explore the profile of Peter Rossing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
614
Citations
20140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Granholm A, Moller M, Kaas-Hansen B, Jensen A, Munch M, Kjaer M, et al.
Acta Anaesthesiol Scand
. 2025 Mar;
69(4):e70023.
PMID: 40084471
Background: Adult intensive care unit (ICU) patients receive many interventions, but few are supported by high-certainty evidence. Randomised clinical trials (RCTs) are essential for trustworthy comparisons of intervention effects, but...
2.
Zohori Bahrami H, Jorgensen P, Hove J, Dixen U, Hartmann Rasmussen L, Eugen-Olsen J, et al.
Diabetes Res Clin Pract
. 2025 Mar;
:112071.
PMID: 40043809
Aims: To investigate the association between chronic inflammation and subclinical left ventricular dysfunction in type 1 diabetes (T1D). Methods: In a cross-sectional study of individuals with T1D without known heart...
3.
Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY
Singh A, James G, Anker S, Pitt B, Rossing P, Ruilope L, et al.
JACC Adv
. 2025 Feb;
4(2):101524.
PMID: 40021271
Background: Anemia is common in patients with chronic kidney disease and type 2 diabetes. Finerenone improved heart and kidney outcomes in patients with chronic kidney disease and type 2 diabetes...
4.
Ostrominski J, Claggett B, Miao Z, Filippatos G, Desai A, Jhund P, et al.
Diabetes Care
. 2025 Feb;
PMID: 40019856
Objective: To evaluate the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in individuals with type 2 diabetes (T2D) and either chronic kidney disease (CKD) or heart failure...
5.
Toft-Hansen H, Aniol-Nielsen C, Elias D, Dahlback M, Rossing P, Sivalingam S, et al.
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40004193
The administration of insulin as a treatment for diabetes frequently leads to the formation of anti-insulin antibodies (IAs). The influence of these antibodies on the efficacy and safety of insulin...
6.
Andersen J, Rasmussen A, Frimodt-Moller M, Kirketerp-Moller K, Rossing P
Clin Med Insights Endocrinol Diabetes
. 2025 Feb;
18:11795514251314787.
PMID: 39995589
Background: Hammertoes is one if not the most common deformity that afflicts the diabetic foot and leads to increased risk of diabetic foot ulcers. Flexor tendon tenotomy treatment of the...
7.
Sridhar V, Kugathasan L, Lovblom L, Huajing N, Lanctot S, Maahs D, et al.
J Am Soc Nephrol
. 2025 Feb;
PMID: 39982799
No abstract available.
8.
Rossing P, Benamar M, Cheng A, Kumar B, Laugesen C, Bajaj H
Diabetes Obes Metab
. 2025 Feb;
27(4):2259-2270.
PMID: 39930546
Aim: This post hoc analysis of ONWARDS 1-5 assessed the efficacy and hypoglycaemia outcomes with once-weekly insulin icodec (icodec) versus once-daily basal insulin comparators (degludec, glargine U100 or glargine U300)...
9.
Agarwal R, Green J, Heerspink H, Mann J, McGill J, Mottl A, et al.
Nephrol Dial Transplant
. 2025 Feb;
PMID: 39916475
Background And Hypothesis: Finerenone, a selective nonsteroidal MRA, and SGLT2is both reduce CKD progression and improve kidney/CV outcomes. The CONFIDENCE study (NCT05254002; EudraCT 2021-003037-11) hypothesis is that early combination of...
10.
Jadoul M, Rossing P
Nephrol Dial Transplant
. 2025 Feb;
40(Supplement_1):i1-i2.
PMID: 39907537
No abstract available.